Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 170-173

  Chouaid, Christos ^a   Dujon, Cecile ^b   Do, Pascal ^c   Monnet, Isabelle ^d   Madroszyk, Anne ^e   Le Caer, Herve ^f   Auliac, Jean Bernard ^g   Berard, Henri ^h   Thomas, Pascal ⁱ   Lena, Herve ^j   Robinet, Gilles ^k   Baize, Nathalie ^l   Bizieux Thaminy, Acya ^m   Fraboulet, Gislaine ⁿ   Locher, Chrystele ^o   Le Treut, Jacques ^p   Hominal, Stephane ^q   Vergnenegre, Alain ^r  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CH André Mignot Le Chesnay   (France)

^c CAC   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^e CAC Marseille   (France)

^f CH de Draguignan   (France)

^g CH F Quesnay Mantes la Jolie   (France)

^h HIA Toulon   (France)

ⁱ Department of Internal Medicine   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k BREST UNIVERSITY HOSPITAL   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m La Roche sur Yon Hospital   (France)

ⁿ CH de Pontoise   (France)

^o CENTRE HOSPITALIER DE MEAUX   (France)

^p Aix en Provence Hospital   (France)

^q CH Annecy Genevois   (France)

^r LIMOGES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Biomarkers; Clinical management; Guidelines; Non small cell lung cancer; Re biopsy

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HEMOPTYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PNEUMOTHORAX; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REPEAT PROCEDURE; BIOPSY; CANCER STAGING; CLINICAL TRIAL; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 84908407258     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.016     Document Type: Article

References (19)

1. Travis W.D., Brambilla E., Riely G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 992-1001.
2. Ellis P.M., Blais N., Soulieres D., et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011, 6:1379-1391.
3. Peters S, Adjei AA, Gridelli C, et al. ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:7:vii56-64.
4. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
6. Sequist L.V., Yang J.C., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
7. Awad M.M., Katayama R., McTigue M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013, 368:2395-2401.
8. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
9. Shaw A.T., Kim D.W., Mehra R., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
10. Sun J.F., Ahn M.J., Choi Y.L., et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 82:294-298.
11. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
12. Sun J.M., Ahn M.J., Choi Y.L., et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013, 82:294-298.
13. Yoon H.J., Lee H.Y., Lee K.S., et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 2012, 265:939-948.
14. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
15. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
16. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
17. Bepler G., Williams C., Schell M.J., et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:2404-2412.
18. Barlesi F BH, Beau-Faller M, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31:abstr 8000.
19. Oxnard G.R., Arcila M.E., Sima C.S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.